Meeting
2023 ASCO Annual Meeting
Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
Authors
Hatem Hussein Soliman
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Hatem Hussein Soliman , Hyo S. Han , Blaise Mooney , Ricardo L Costa , Marie Catherine Lee , Bethany Niell , Alec Chau , Shannon Falcon , Aixa Elena Soyano Muller , Avan J. Armaghani , Nazanin Khakpour , Robert J Weinfurtner , Susan Hoover , John Kiluk , Christine Laronga , Marilin Rosa , Hung T. Khong , Brian J. Czerniecki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02779855
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 598)
DOI
10.1200/JCO.2023.41.16_suppl.598
Abstract #
598
Poster Bd #
428
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).
First Author: David B. Page
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2021 ASCO Annual Meeting
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
First Author: Hatem Hussein Soliman
Poster
2019 ASCO Annual Meeting
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.
First Author: Raquel Nunes